Patent 12060390 was granted and assigned to Ginkgo Bioworks on August, 2024 by the United States Patent and Trademark Office.
The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.